Role of spiramycin in prevention of fetal toxoplasmosis

Avci, Muhittin Eftal; Arslan, Ferhat; Ciftci, S; Ekiz, Ali; Tüten, Abdullah; Yıldırım, Gökhan; Madazli, Rıza

doi:10.3109/14767058.2015.1074998

Cited by 12 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence was presented that spiramycin therapy during pregnancy can reduce congenital transmission of T. gondii (Avci et al ., 2016). Of the 61 women who acquired T. gondii infection during pregnancy, 55 (90.2%) received spiramycin prophylaxis while six (6.6%) refused it.…”

Section: Toxoplasmosis In Humansmentioning

confidence: 99%

A review of toxoplasmosis in humans and animals in Turkey

Kolören

Dubey

2019

Parasitology

View full text Add to dashboard Cite

Infections by the protozoan parasite Toxoplasma gondii are widely prevalent in humans and animals in Turkey but little is known of the burden of their clinical toxoplasmosis. Many early papers on toxoplasmosis in Turkey were published in Turkish and often not available widely. Here, we review prevalence, clinical spectrum, epidemiology and diagnosis of T. gondii in humans and animals in Turkey. This knowledge should be useful to biologists, public health workers, veterinarians and physicians. Although one-third of the human population in Turkey is seropositive, the rate of congenital toxoplasmosis is unknown and no information is available in children 12 years old or younger. One large outbreak of acute toxoplasmosis has been reported in 14–18-year old school children in Turkey. An alarming rate (36%) of T. gondii tissue cysts were reported in tissues of sheep and water buffalo meats destined for human consumption; these reports require verification. Genetically, T. gondii strains from domestic cats and wild birds in Turkey were generally classical type II and III, like those prevalent in Europe. A separate genotype, Type 1 Africa, was isolated from two congenitally infected children and a domestic cat in Turkey.

show abstract

Section: Toxoplasmosis In Humansmentioning

confidence: 99%

A review of toxoplasmosis in humans and animals in Turkey

Kolören

Dubey

2019

Parasitology

View full text Add to dashboard Cite

show abstract

“…In studies investigating the efficacy of treatment, it was reported that parasite transmission from the mother to the child was higher in untreated pregnant women, and spyramicine prophylaxis was found to be effective for preventing CT. In addition, it has been shown that early diagnosis and treatment can reduce the mother-to-child transmission of the parasite, and can also reduce the disease’s severity in the infected fetus [ 18 , 20 , 25 , 26 ]. However, the SYROCOT study did not find robust evidence for a link between early treatment and decreased risk of CT [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Toxoplasmosis: A Timeless Challenge for Pregnancy

et al. 2023

View full text Add to dashboard Cite

This study aimed to evaluate the prevalence of toxoplasmosis in pregnant women, as well as the general characteristics, clinical and laboratory findings, and pregnancy and fetal outcomes of pregnant women diagnosed with acute toxoplasma infection (ATI). The toxoplasma IgM, IgG, and IgG avidity test results of pregnant women who applied to our referral hospital between January 2016 and June 2022, and among them, those diagnosed with ATI, were analyzed. The 119 patients diagnosed with ATI during this time period were included for further analysis. The prevalence of toxoplasmosis in pregnant women was found to be 46.2%, and the rate of ATI was 4%. The total mother-to-child transmission rate was 5% (5/101). Congenital toxoplasmosis (CT) was observed in 1 (1.1%) child of the 87 pregnant women who received spiramycin prophylaxis, though it was found in 4 (30.8%) of the children of the 13 untreated mothers. With respect to prenatal treatment, CT rates were significantly higher in the children born to untreated mothers (p = 0.001). In conclusion, although toxoplasma seroprevalence was found to be high in our region, there was a paucity in diagnosis, follow-up, and treatment. Our findings support that prenatal spiramycin prophylaxis is effective in preventing the transmission of parasites from mother to child.

show abstract

“…This drug is described in the literature as a therapeutic option, especially in immunocompromised patients, but more studies are necessary to validate this approach in pregnant women. 18,23,26,[33][34][35][36][37] Although infrequent, triple therapy may lead to serious complications. Prescribing these medications for all patients who become infected in the third trimester and do not perform the propaedeutic study for fetal research may increase the risk of adverse reactions in individuals who may not need these drugs.…”

Section: Discussionmentioning

confidence: 99%

Follow-up of Toxoplasmosis during Pregnancy: Ten-Year Experience in a University Hospital in Southern Brazil

Diesel

Záchia

Müller

et al. 2019

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective To describe a population of pregnant women diagnosed with toxoplasmosis and their respective newborns, describing the hospital protocol for treatment and follow-up. Methods Retrospective cohort of pregnant women with acute toxoplasmosis infection and risk of transplacental transmission who were sent to the Fetal Medicine Group of Hospital de Clínicas de Porto Alegre (HCPA) between -January 1, 2006 and December 31, 2016. All patients with confirmed disease were included. The diagnostic protocol and treatment were applied; a polymerase chain reaction (PCR) analysis of the amniotic fluid was used to diagnose toxoplasmosis and determine the treatment. The newborns were followed up at the pediatric outpatient clinic specializing in congenital infection. The patients who were not followed up or were not born in the HCPA were excluded. Results A total of 65 patients were confirmed to have gestational toxoplasmosis; 40 performed amniocentesis, and 6 (15%) were identified as having positive PCR in the amniotic fluid. In five of those cases, this result associated with the gestational age defined the triple therapy during pregnancy, and in one case, it defined the monotherapy (advanced gestational age). A total of 4 of these newborns were treated from birth with triple therapy for 10 months, 1 was not treated (due to maternal refusal), and 1 progressed to death within the first 54 hours of life due to complications of congenital toxoplasmosis. Of the 34 remaining cases with a negative PCR, 33 were treated with monotherapy and 1 was treated with triple therapy (ultrasound findings); of these children, 9 (26.5%) presented negative immunoglobulin G (IgG), 24 (70.6%) presented Ana Lúcia Letti Müller's ORCID is https://orcid.org/0000-0003-1214-5664.

show abstract

Role of spiramycin in prevention of fetal toxoplasmosis

Abstract: Our results seem to encourage the use of spiramycin in women with toxoplasmosis during pregnancy.

Cited by 12 publications

References 19 publications

A review of toxoplasmosis in humans and animals in Turkey

A review of toxoplasmosis in humans and animals in Turkey

Toxoplasmosis: A Timeless Challenge for Pregnancy

Follow-up of Toxoplasmosis during Pregnancy: Ten-Year Experience in a University Hospital in Southern Brazil

Contact Info

Product

Resources

About